It was reported yesterday that Mayne Pharma, a fast growing company, focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, has acquired the US and Australian rights to halobetasol foam 0.05%.
The deal is valued for a sum of up to USD32m, which includes contingent payments of up to USD17m based on commercial milestones and other factors.
In addition, there is an ongoing earn-out payment based as a percentage of net sales over a 10-year period.
According to the terms of the asset purchase, license and commercialisation agreement, Mayne Pharma has also acquired the approved US regulatory filing, medical and technical data, and a portfolio of pending US patent applications.This product received US Food and Drug Administration approval in May 2018 and Mayne Pharma is planning for the commercial launch of this product in early 2019. The product received three years of marketing exclusivity and has four pending patent applications with the US Patent and Trademark Office.
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US
Amneal passes US FDA approval for marketing Carmustine for Injection USP in 100 mg/vial
Mylan launches Medroxyprogesterone Acetate Injectable Suspension USP in US
Dr Reddy's Laboratories to divest Hyderabad API manufacturing business unit to Therapiva Private
Dr. Reddy's Laboratories divests API manufacturing business unit in Jeedimetla, Hyderabad, India
Breckenridge awarded US FDA approval for Roflumilast Tablets (Daliresp) ANDA
ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets
Dr. Reddy's Laboratories Has Regained Worldwide Rights to DFA-02
Dr. Reddy's Laboratories Launches Imatinib Mesylate Tablets, USP in the US Market